Trusted by:
Results from a research study supported by the Cancer Research Institute indicates that the suppressive immune tendencies of CD4+ regulatory T cells can be regulated, thus overcoming a huge hurdle faced when crafting a cancer vaccine.
The Cancer Research Institute has established a unique collaboration with three other major U.S. research institutions that will work together to unlock the molecular and genetic mysteries behind Zheng Cui's SR/CR mouse's remarkable cancer immunity.
Cancer Vaccine Collaborative scientists announce that results from a study of a new vaccination strategy indicate the vaccine had a favorable impact on disease progression in late-stage melanoma patients. The vaccine is composed of recombinant fowlpox and vaccinia viruses engineered to express the Cancer-Testis antigen NY-ESO-1.
Cancer Research Institute supported scientists have proven that dormant cancer cells are actively kept in check by the immune system, while those that escape go on to develop into clinically detectable tumors. A paper online in this week's Nature identifies a crucial stage in the battle, at which point immune defenses stall the expansion of cancer cells that may have managed to dodge past early immunosurveillance.
A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.
Cancer researchers have taken a major step forward toward what is planned to be the most comprehensive analysis of the body’s antibody response to human cancer, an enterprise that has been termed “cancer seromics.”
The laboratory of Dr. Lloyd J. Old of the Ludwig Institute for Cancer Research (LICR), together with Dr. Yao-Tseng Chen at Weill Cornell Medical College and their collaborators, made the finding that CT45, a cancer/testis (CT) antigen normally expressed in testicular germ cells in both prenatal and adult life, is expressed by the Reed-Sternberg cells in most of the classical Hodgkin lymphomas. The finding has implications for diagnostic, prognostic, and therapeutic approaches for Hodgkin lymphoma.
A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.
Tumor immunologists are hailing the first FDA approval of a therapeutic cancer vaccine as a milestone victory, but many experts agree more research is needed to optimize cancer vaccines.
First treatment ever proven in a randomized trial to extend life for patients whose melanomas are unresponsive to existing cancer therapies.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right